



Ascendis
HEALTH

**TRANSACTION INTRODUCTION
– SCITEC NUTRITION
– REMEDICA**



DISCLAIMER



The information contained in this Presentation was obtained from Ascendis, the Target Companies and/or other sources and has not been verified by Ascendis, the Target Companies, their respective affiliates or any of their respective directors, officers, partners, employees, agents, representatives and advisers.

None of Ascendis, the Target Companies, their respective affiliates or any of their respective directors, officers, partners, employees, agents, representatives and advisers makes any representation or warranty, express or implied, as to the accuracy or completeness of the information contained in the Presentation or as to the reasonableness of any assumption contained herein and, so far as is permitted by law, any and all responsibility and liability therefore, (including in respect of direct, indirect or consequential loss or damage) is expressly disclaimed. Nothing contained herein is, or shall be relied upon as, a promise or representation or warranty, whether as to the past or the future. The Presentation does not purport to contain all of the information that may be required to evaluate the Transaction and/or the Target Companies and any recipient hereof should seek its own financial, legal and other advice and conduct its own independent investigation and analysis of Ascendis, the Target Companies and their respective financial conditions and prospects and the data contained or referred to herein. By accepting the Presentation, the recipient confirms that it is sufficiently expert to understand the risks involved in the Transaction

The information contained herein has been prepared using information available to Ascendis at the time of preparation of the Presentation. External or other factors may have impacted on the business of Ascendis and the content of this Presentation, since its preparation. In addition, all relevant information about Ascendis may not be included in this Presentation. The information in this Presentation has not been independently verified. Neither Ascendis, nor any of its advisers, connected persons or any other person accepts any liability for any loss howsoever arising, directly or indirectly, from this Presentation or its contents. This Presentation is not intended to form the basis of any investment decision and should not be considered as a recommendation by Ascendis, the Target Companies, their respective affiliates or any of their respective directors, officers, partners, employees, agents, representatives and advisers in relation to Ascendis and/or the Transaction, or the giving of any advice in connection therewith. This Presentation is not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident of, or located in, any locality, state, country or other jurisdiction where such distribution or use would be contrary to law or regulation or which would require any action (including registration or licensing) within such jurisdiction for such purpose. This Presentation (including oral or written communications in connection with the Transaction) does not constitute in any jurisdiction an offer or invitation for the sale or purchase of, or subscription for, any securities in Ascendis or the solicitation of any of the foregoing.

OVERVIEW OF EQUITY RAISE




ISSUER	Ascendis Health Limited
NOTIONAL AMOUNT	Total of up to R2.4bn that will be raised through an up to R1.2bn Rights Issue followed by an up to R1.2bn vendor consideration placing
USES	Funding the acquisition of Remedica and Scitec
INDICATIVE TIMETABLE	Rights issue subscription period: Mid July 2016 Vendor placement execution: Early August 2016
SHAREHOLDER SUPPORT	<p>The announced M&A transactions and equity financing have received strong support from existing shareholders and new investors:</p> <p>C.63% of current Ascendis holders have provided written undertakings to support the proposed Rights Issue and vendor placing</p> <p>Coast2Coast (43% current holder) is committed to follow its rights under the Rights Issue and has allocated any portion of its rights not taken up through back-to-back commitments</p> <p>The International Finance Corporation ("IFC") and another prominent international investor have committed USD30m and ZAR180m respectively into the vendor placing</p>

Ascendis has appointed HSBC and Absa to jointly underwrite the total debt facilities required with the intention to syndicate to broad financing group

Indicative quantum	<ul style="list-style-type: none">• €160 -190m offshore• ZAR500m local	
	Offshore assets	4.00x
Net Leverage Ratios	Local assets	3.00x
	Total	3.52x
	Total leverage will be reduced to 3.0x within 18 months	



INTRODUCTION TO SCITEC AND REMEDICA



PRODUCT OVERVIEW



Protein powders



Muscle gainers



Pre-workout energizers



Protein RTDs ¹



Amino acids



Creatines and glutamines



Energy RTDs ¹



Protein bars



Fat burners




Vitamins, minerals, essentials




Scitec offers a full sports nutrition “shelf” solution for the retailer, making direct purchases attractive




SCITEC'S GLOBAL PRESENCE




Sales



Gross Profit



EBITDA






REMEDICA HAS ~300 PRODUCTS AND ~2500 MARKETING LICENSES





REMEDICA'S GLOBAL PRESENCE





PROCESS



INDICATIVE TIMETABLE

- This early stage investor roadshow constitutes a preliminary introduction to the opportunity to participate in the capital raise as part of the funding consideration of the Remedica and Scitec acquisitions

